

Supplementary Table 2. Age-stratified neutralizing antibody responses for A/H3N2 and B/Brisbane in the per-protocol immunogenicity cohort (Day 0 and Day 28) and the per-protocol immunogenicity persistence cohort (Month 6)

	Time point	N	6 months–9 years	N	6–11 months	N	12–35 months	N	3–9 years	N	10–17 years
A/Perth/16/2006 (H3N2)†											
Seropositive, % (95% CI)	Day 0	65	80.0%	7	57.1%	35	74.3%	23	95.7%	33	90.9%
			(68.2–88.9)		(18.4–90.1)		(56.7–87.5)		(78.1–99.9)		(75.7–98.1)
	Day 28	64	100%	7	100%	34	100%	23	100%	33	100%
			(94.4–100)		(59.0–100)		(89.7–100)		(85.2–100)		(89.4–100)
	Month 6	56	100%	6	100%	28	100%	22	100%	35	100%
			(93.6–100)		(54.1–100)		(87.7–100)		(84.6–100)		(90.0–100)
VRR, % (95% CI)	Day 28	64	81.3%	7	57.1%	34	94.1%	23	69.6%	33	66.7%
			(69.5–89.9)		(18.4–90.1)		(80.3–99.3)		(47.1–86.8)		(48.2–82.0)
	Month 6	56	69.6%	6	83.3%	28	75.0%	22	59.1%	35	48.6%
			(55.9–81.2)		(35.9–99.6)		(55.1–89.3)		(36.4–79.3)		(31.4–66.0)
GMT, value (95% CI)	Day 0	65	90.5	7	30.0	35	84.9	23	139.5	33	69.8
			(67.4–121.6)		(13.5–66.9)		(53.7–134.5)		(100.8–193.0)		(50.5–96.5)
	Day 28	64	832.9	7	90.1	34	1011.6	23	1229.9	33	614.5
			(514.7–1347.8)		(50.1–162.0)		(509.5–2008.6)		(586.5–2579.3)		(371.4–1016.7)
	Month 6	56	571.5	6	264.1	28	618.2	22	638.2	35	266.8
			(435.5–749.8)		(136.0–512.9)		(435.1–878.5)		(381.1–1068.8)		(173.6–410.1)
B/Brisbane/60/2008											

	Time point	N	6 months–9 years	N	6–11 months	N	12–35 months	N	3–9 years	N	10–17 years
Seropositive, % (95% CI)	Day 0	65	20.0 (11.1–31.8)	7	14.3% (0.4–57.9)	35	14.3% (4.8–30.3)	23	30.4% (13.2–52.9)	33	51.5% (33.5–69.2)
	Day 28	64	46.9% (34.3–59.8)	7	42.9% (9.9–81.6)	34	44.1% (27.2–62.1)	23	52.2% (30.6–73.2)	33	93.9% (79.8–99.3)
	Month 6	56	92.9% (82.7–98.0)	6	100% (54.1–100)	28	100% (87.7–100)	18	81.8% (59.7–94.8)	35	97.1% (85.1–99.9)
	Day 28	64	39.1% (27.1–52.1)	7	42.9% (9.9–81.6)	34	32.4% (17.4–50.5)	23	47.8% (26.8–69.4)	33	75.8% (57.7–88.9)
	Month 6	56	75.0% (61.6–85.6)	6	100.0% (54.1–100.0)	28	82.1% (63.1–93.9)	22	59.1% (36.4–79.3)	35	80.0% (63.1–91.6)
	Day 0	65	21.3 (16.8–26.9)	7	20.2 (8.3–49.2)	35	19.1 (13.9–26.2)	23	25.4 (16.6–38.9)	33	26.0 (20.2–33.6)
GMT, value (95% CI)	Day 28	64	54.3 (33.0–89.3)	7	49.3 (6.9–349.5)	34	42.3 (20.9–85.5)	23	80.8 (34.8–187.9)	33	257.9 (158.5–419.5)
	Month 6	56	138.9 (95.2–202.6)	6	284.5 (89.4–905.6)	28	140.0 (81.7–240.0)	18	113.1 (58.2–219.7)	35	199.5 (145.8–273.0)

CI, confidence interval; N, number of subjects in group; GMT, geometric mean titer; VRR, vaccine response rate; TIV, trivalent inactivated influenza vaccine. Age ranges refer to age at time of AS03-adjuvanted A(H1N1)pdm09 vaccination.

VRR defined as proportion of subjects achieving an increase in antibody titer from <1:28 to ≥1:32 or at least a 4-fold post-vaccination increase in titer from a pre-vaccination titer ≥1:28; seropositive defined as a titer of ≥1:28

†Due to an issue with the assay, the A/H3N2 microneutralizing test was performed using A/Perth/16/2006 rather than A/Victoria/210/2009 (A/Victoria is a Perth-like strain)